ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signalingBaorui Tao|Clinical and Molecular Hepatology|2026Cited by 1